研究园简易版
·
经典书籍
·
期刊文章
·
有原文
·
完整版(可多选筛选、搜索)
·
首页
搜索
2016 年 · Clinical Trials(临床试验)
137 篇,新的在前。点标题看作者和摘要。
回到 2016 年
Adjusting for bias in unblinded randomized controlled trials
· SMMR · 2016-12-29 · 在第 1 页
Point estimation and p‐values in phase II adaptive two‐stage designs with a binary endpoint
· SiM · 2016-12-27 · 在第 1 页
Imbalance properties of centre‐stratified permuted‐block and complete randomisation for several treatments in a clinical trial
· SiM · 2016-12-27 · 在第 1 页
Assessing treatment efficacy in the presence of diagnostic errors
· SiM · 2016-12-20 · 在第 1 页
Sample size calculations for group randomized trials with unequal group sizes through Monte Carlo simulations
· SMMR · 2016-12-15 · 在第 1 页
Supplementation of a clinical trial by historical control data: is the prospect of dynamic borrowing an illusion?
· SiM · 2016-12-07 · 在第 2 页
Is the classical Wald test always suitable under response-adaptive randomization?
· SMMR · 2016-12-05 · 在第 2 页
Generalized Semiparametric Varying-Coefficient Model for Longitudinal Data with Applications to Adaptive Treatment Randomizations
· Biometrics · 2016-12-05 · 在第 2 页
A more efficient three-arm non-inferiority test based on pooled estimators of the homogeneous variance
· SMMR · 2016-12-05 · 在第 2 页
Tutorial on statistical considerations on subgroup analysis in confirmatory clinical trials
· SiM · 2016-11-28 · 在第 2 页
Developing a Bayesian adaptive design for a phase I clinical trial: a case study for a novel HIV treatment
· SiM · 2016-11-27 · 在第 3 页
Linear-rank testing of a non-binary, responder-analysis, efficacy score to evaluate pharmacotherapies for substance use disorders
· SMMR · 2016-11-25 · 在第 3 页
A U -statistics based approach to sample size planning of two-arm trials with discrete outcome criterion aiming to establish either superiority or noninferiority
· SiM · 2016-11-22 · 在第 3 页
Sample size and power for a stratified doubly randomized preference design
· SMMR · 2016-11-21 · 在第 3 页
Inconsistency and drop‐minimum data analysis
· SiM · 2016-11-21 · 在第 3 页
A time‐varying effect model for examining group differences in trajectories of zero‐inflated count outcomes with applications in substance abuse research
· SiM · 2016-11-21 · 在第 3 页
The asymptotic maximal procedure for subject randomization in clinical trials
· SMMR · 2016-11-16 · 在第 3 页
Sample size calculation for agreement between two raters with binary endpoints using exact tests
· SMMR · 2016-11-16 · 在第 3 页
A studentized permutation test for three‐arm trials in the ‘gold standard’ design
· SiM · 2016-11-16 · 在第 3 页
Inference and sample size calculation for clinical trials with incomplete observations of paired binary outcomes
· SiM · 2016-11-10 · 在第 3 页
Asymmetric inner wedge group sequential tests with applications to verifying whether effective drug concentrations are similar in adults and children
· SiM · 2016-11-08 · 在第 3 页
Factorial versus multi-arm multi-stage designs for clinical trials with multiple treatments
· SiM · 2016-11-02 · 在第 4 页
Designing therapeutic cancer vaccine trials with delayed treatment effect
· SiM · 2016-11-02 · 在第 4 页
On the estimation of intracluster correlation for time-to-event outcomes in cluster randomized trials
· SiM · 2016-10-27 · 在第 4 页
Reader Reaction on Estimation of Treatment Effects in All-Comers Randomized Clinical Trials with a Predictive Marker
· Biometrics · 2016-10-24 · 在第 4 页
Alternating Logistic Regressions with Improved Finite Sample Properties
· Biometrics · 2016-10-24 · 在第 4 页
A Subgroup Cluster-Based Bayesian Adaptive Design for Precision Medicine
· Biometrics · 2016-10-24 · 在第 4 页
Unified approach for extrapolation and bridging of adult information in early-phase dose-finding paediatric studies
· SMMR · 2016-10-05 · 在第 5 页
Estimation after blinded sample size reassessment
· SMMR · 2016-10-02 · 在第 5 页
On a class of optimal covariate-adjusted response adaptive designs for survival outcomes
· SMMR · 2016-09-30 · 在第 6 页
Multilevel models for cost-effectiveness analyses that use cluster randomised trial data: An approach to model choice
· SMMR · 2016-09-30 · 在第 6 页
Analysis of clustered competing risks data using subdistribution hazard models with multivariate frailties
· SMMR · 2016-09-30 · 在第 7 页
A multi-stage drop-the-losers design for multi-arm clinical trials
· SMMR · 2016-09-30 · 在第 7 页
A comparison of machine learning methods for classification using simulation with multiple real data examples from mental health studies
· SMMR · 2016-09-30 · 在第 7 页
Choosing appropriate analysis methods for cluster randomised cross‐over trials with a binary outcome
· SiM · 2016-09-28 · 在第 7 页
Optimally estimating the sample mean from the sample size, median, mid-range, and/or mid-quartile range
· SMMR · 2016-09-27 · 在第 7 页
Testing Violations of the Exponential Assumption in Cancer Clinical Trials with Survival Endpoints
· Biometrics · 2016-09-26 · 在第 7 页
Comparing a stratified treatment strategy with the standard treatment in randomized clinical trials
· SiM · 2016-09-25 · 在第 7 页
Testing of non-inferiority and superiority for three-arm clinical studies with multiple experimental treatments
· SMMR · 2016-09-19 · 在第 7 页
Recommendations on multiple testing adjustment in multi-arm trials with a shared control group
· SMMR · 2016-09-19 · 在第 7 页
Optimal sequential enrichment designs for phase II clinical trials
· SiM · 2016-09-19 · 在第 7 页
A Bayesian dose‐finding design incorporating toxicity data from multiple treatment cycles
· SiM · 2016-09-15 · 在第 8 页
Designs for phase I trials in ordered groups
· SiM · 2016-09-14 · 在第 8 页
Sequential Multiple Assignment Randomization Trials with Enrichment Design
· Biometrics · 2016-09-06 · 在第 8 页
Detecting and accounting for violations of the constancy assumption in non-inferiority clinical trials
· SMMR · 2016-09-01 · 在第 8 页
Confidence and coverage for Bland–Altman limits of agreement and their approximate confidence intervals
· SMMR · 2016-09-01 · 在第 8 页
Analysis of phase II methodologies for single-arm clinical trials with multiple endpoints in rare cancers: An example in Ewing’s sarcoma
· SMMR · 2016-09-01 · 在第 8 页
A practical Bayesian design to identify the maximum tolerated dose contour for drug combination trials
· SiM · 2016-08-31 · 在第 9 页
Multi‐arm group sequential designs with a simultaneous stopping rule
· SiM · 2016-08-23 · 在第 9 页
A Bayesian adaptive phase I–II trial design for optimizing the schedule of therapeutic cancer vaccines
· SiM · 2016-08-21 · 在第 9 页
Joint Estimation of Treatment and Placebo Effects in Clinical Trials With Longitudinal Blinding Assessments
· JASA · 2016-08-18 · 在第 10 页
Active Clinical Trials for Personalized Medicine
· JASA · 2016-08-18 · 在第 10 页
A robust two‐stage design identifying the optimal biological dose for phase I/II clinical trials
· SiM · 2016-08-18 · 在第 10 页
Sample size and classification error for Bayesian change-point models with unlabelled sub-groups and incomplete follow-up
· SMMR · 2016-08-08 · 在第 10 页
Tutorial in biostatistics: data‐driven subgroup identification and analysis in clinical trials
· SiM · 2016-08-03 · 在第 11 页
On the win-ratio statistic in clinical trials with multiple types of event
· Biometrika · 2016-07-25 · 在第 12 页
Two-stage seamless transition design from open-label single-arm to randomized double-arm clinical trials
· SMMR · 2016-07-20 · 在第 12 页
Performance of toxicity probability interval based designs in contrast to the continual reassessment method
· SiM · 2016-07-19 · 在第 12 页
Estimands in clinical trials – broadening the perspective
· SiM · 2016-07-19 · 在第 12 页
An adaptive design for updating the threshold value of a continuous biomarker
· SiM · 2016-07-14 · 在第 12 页
Use of auxiliary covariates in estimating a biomarker-adjusted treatment effect model with clinical trial data
· SMMR · 2016-07-11 · 在第 13 页
Survival estimation in two-phase cohort studies with application to biomarkers evaluation
· SMMR · 2016-07-11 · 在第 13 页
Statistical methods for the analysis of clinical trials data containing many zeros: An application in vaccine development
· SMMR · 2016-07-11 · 在第 13 页
Simulating the contribution of a biospecimen and clinical data repository in a phase II clinical trial: A value of information analysis
· SMMR · 2016-07-11 · 在第 13 页
Sample size determinations for group-based randomized clinical trials with different levels of data hierarchy between experimental and control arms
· SMMR · 2016-07-11 · 在第 13 页
Sample size calculations for prevalent cohort designs
· SMMR · 2016-07-11 · 在第 13 页
Notes on testing noninferiority in multivariate binary data under the matched-pair design
· SMMR · 2016-07-11 · 在第 13 页
Multiple-stage sampling procedure for covariate-adjusted response-adaptive designs
· SMMR · 2016-07-11 · 在第 13 页
Likelihood Ratio Tests for a Dose-Response Effect Using Multiple Nonlinear Regression Models
· Biometrics · 2016-07-11 · 在第 14 页
Increasing efficiency for estimating treatment–biomarker interactions with historical data
· SMMR · 2016-07-11 · 在第 14 页
Binomial confidence intervals for testing non-inferiority or superiority: a practitioner’s dilemma
· SMMR · 2016-07-11 · 在第 14 页
An adaptive clinical trials procedure for a sensitive subgroup examined in the multiple sclerosis context
· SMMR · 2016-07-11 · 在第 15 页
Adjusted inference procedures for the interobserver agreement in twin studies
· SMMR · 2016-07-11 · 在第 15 页
A comparison of imputation strategies in cluster randomized trials with missing binary outcomes
· SMMR · 2016-07-11 · 在第 15 页
A comparative study of matched pair designs with two binary endpoints
· SMMR · 2016-07-11 · 在第 15 页
The rapid enrollment design for Phase I clinical trials
· SiM · 2016-07-10 · 在第 15 页
Non-randomized and randomized stepped-wedge designs using an orthogonalized least squares framework
· SMMR · 2016-07-10 · 在第 15 页
A Bayesian multi-stage cost-effectiveness design for animal studies in stroke research
· SMMR · 2016-07-08 · 在第 15 页
Exact confidence limits for the response rate in two-stage designs with over- or under-enrollment in the second stage
· SMMR · 2016-07-07 · 在第 15 页
Sample size calculation for stepped wedge and other longitudinal cluster randomised trials
· SiM · 2016-06-28 · 在第 16 页
Sequential designs with small samples: Evaluation and recommendations for normal responses
· SMMR · 2016-06-24 · 在第 16 页
Measuring the individual benefit of a medical or behavioral treatment using generalized linear mixed‐effects models
· SiM · 2016-06-20 · 在第 16 页
The analysis of terminal endpoint events in stepped wedge designs
· SiM · 2016-06-16 · 在第 16 页
Efficient treatment allocation in 2 × 2 cluster randomized trials, when costs and variances are heterogeneous
· SiM · 2016-06-07 · 在第 17 页
Three measures of explained variation for correlated survival data under the proportional hazards mixed‐effects model
· SiM · 2016-05-30 · 在第 17 页
Model selection versus model averaging in dose finding studies
· SiM · 2016-05-25 · 在第 17 页
A novel complete-case analysis to determine statistical significance between treatments in an intention-to-treat population of randomized clinical trials involving missing data
· SMMR · 2016-05-25 · 在第 17 页
Missing continuous outcomes under covariate dependent missingness in cluster randomised trials
· SMMR · 2016-05-13 · 在第 18 页
An adaptive dose‐finding method using a change‐point model for molecularly targeted agents in phase I trials
· SiM · 2016-05-11 · 在第 18 页
A Bayesian Credible Subgroups Approach to Identifying Patient Subgroups with Positive Treatment Effects
· Biometrics · 2016-05-09 · 在第 18 页
Bayesian optimal response-adaptive design for binary responses using stopping rule
· SMMR · 2016-05-02 · 在第 19 页
On Confidence Intervals for the Hazard Ratio in Randomized Clinical Trials
· Biometrics · 2016-04-28 · 在第 19 页
MIDAS: a practical Bayesian design for platform trials with molecularly targeted agents
· SiM · 2016-04-25 · 在第 20 页
Assessing methods for dealing with treatment switching in clinical trials: A follow-up simulation study
· SMMR · 2016-04-25 · 在第 20 页
Unbiased estimation in seamless phase II/III trials with unequal treatment effect variances and hypothesis‐driven selection rules
· SiM · 2016-04-21 · 在第 20 页
Likelihood ratio and score tests to test the non-inferiority (or equivalence) of the odds ratio in a crossover study with binary outcomes
· SiM · 2016-04-19 · 在第 20 页
Testing of evaluation bias for progression free survival endpoint in oncology clinical trials
· SiM · 2016-04-18 · 在第 20 页
Targeted estimation and inference for the sample average treatment effect in trials with and without pair‐matching
· SiM · 2016-04-18 · 在第 20 页
Dimension of model parameter space and operating characteristics in adaptive dose‐finding studies
· SiM · 2016-04-18 · 在第 20 页
Group sequential designs with prospectively planned rules for subpopulation enrichment
· SiM · 2016-04-13 · 在第 20 页
A Bayesian adaptive design for estimating the maximum tolerated dose curve using drug combinations in cancer phase I clinical trials
· SiM · 2016-04-07 · 在第 21 页
Power/sample size calculations for assessing correlates of risk in clinical efficacy trials
· SiM · 2016-03-31 · 在第 21 页
New insights into the evaluation of randomized controlled trials for rare diseases over a long‐term research horizon: a simulation study
· SiM · 2016-03-30 · 在第 21 页
Adaptive dose modification for phase I clinical trials
· SiM · 2016-03-29 · 在第 22 页
Optimal flexible sample size design with robust power
· SiM · 2016-03-21 · 在第 22 页
Study duration for three-arm non-inferiority survival trials designed for accrual by cohorts
· SMMR · 2016-03-17 · 在第 22 页
Simultaneous Inference on Treatment Effects in Survival Studies with Factorial Designs
· Biometrics · 2016-03-17 · 在第 22 页
Sample size determinations for stepped-wedge clinical trials from a three-level data hierarchy perspective
· SMMR · 2016-03-17 · 在第 22 页
Phase I/II dose-finding design for molecularly targeted agent: Plateau determination using adaptive randomization
· SMMR · 2016-03-17 · 在第 22 页
Modelling the distribution of health-related quality of life of advanced melanoma patients in a longitudinal multi-centre clinical trial using M-quantile random effects regression
· SMMR · 2016-03-17 · 在第 22 页
Identification of predicted individual treatment effects in randomized clinical trials
· SMMR · 2016-03-17 · 在第 22 页
Extrapolation of efficacy and other data to support the development of new medicines for children: A systematic review of methods
· SMMR · 2016-03-17 · 在第 22 页
A default method to specify skeletons for Bayesian model averaging continual reassessment method for phase I clinical trials
· SiM · 2016-03-16 · 在第 23 页
Multiple imputation methods for bivariate outcomes in cluster randomised trials
· SiM · 2016-03-14 · 在第 23 页
A marginal rank‐based inverse normal transformation approach to comparing multiple clinical trial endpoints
· SiM · 2016-03-14 · 在第 23 页
Repeated significance tests of linear combinations of sensitivity and specificity of a diagnostic biomarker
· SiM · 2016-03-07 · 在第 23 页
Implementation of adaptive methods in early‐phase clinical trials
· SiM · 2016-02-29 · 在第 23 页
Intra‐cluster correlation selection for cluster randomized trials
· SiM · 2016-02-28 · 在第 23 页
Type‐II generalized family‐wise error rate formulas with application to sample size determination
· SiM · 2016-02-23 · 在第 24 页
Identifying a maximum tolerated contour in two‐dimensional dose finding
· SiM · 2016-02-22 · 在第 24 页
Modelling semi‐attributable toxicity in dual‐agent phase I trials with non‐concurrent drug administration
· SiM · 2016-02-19 · 在第 24 页
Joint Model for Left-Censored Longitudinal Data, Recurrent Events and Terminal Event: Predictive Abilities of Tumor Burden for Cancer Evolution With Application to the FFCD 2000–05 Trial
· Biometrics · 2016-02-17 · 在第 24 页
Estimating Optimal Shared-Parameter Dynamic Regimens with Application to a Multistage Depression Clinical Trial
· Biometrics · 2016-02-17 · 在第 24 页
Inference on treatment‐covariate interaction based on a nonparametric measure of treatment effects and censored survival data
· SiM · 2016-02-16 · 在第 24 页
Analyzing clinical trial outcomes based on incomplete daily diary reports
· SiM · 2016-02-16 · 在第 24 页
Sequential monitoring of Phase I dose expansion cohorts
· SiM · 2016-02-07 · 在第 25 页
Design and analysis of clinical trials in the presence of delayed treatment effect
· SiM · 2016-02-02 · 在第 25 页
Assessing the consistency of the treatment effect under the discrete random effects model in multiregional clinical trials
· SiM · 2016-02-02 · 在第 25 页
Estimating Treatment Effect in a Proportional Hazards Model in Randomized Clinical Trials with All-or-Nothing Compliance
· Biometrics · 2016-01-22 · 在第 26 页
Repairing the efficiency loss due to varying cluster sizes in two‐level two‐armed randomized trials with heterogeneous clustering
· SiM · 2016-01-12 · 在第 26 页
Controlled multi-arm platform design using predictive probability
· SMMR · 2016-01-12 · 在第 26 页
An objective re‐evaluation of adaptive sample size re‐estimation: commentary on ‘Twenty‐five years of confirmatory adaptive designs’
· SiM · 2016-01-12 · 在第 26 页
Evidence, eminence and extrapolation
· SiM · 2016-01-11 · 在第 26 页
Statistical efficiency and optimal design for stepped cluster studies under linear mixed effects models
· SiM · 2016-01-07 · 在第 27 页
Low‐event‐rate meta‐analyses of clinical trials: implementing good practices
· SiM · 2016-01-05 · 在第 27 页
The Constrained Dantzig Selector with Enhanced Consistency
· JMLR · 2016 · 在第 28 页
Extracting PICO Sentences from Clinical Trial Reports using Supervised Distant Supervision
· JMLR · 2016 · 在第 32 页